Fournier Laboratories Ireland Ltd.

The primary objective of this study is to evaluate the efficacy of ABT-493/ABT-530 in combination with SOF and RBV by evaluating the percentage of subjects in each treatment group who achieve a sustained virologic response 12 weeks after the end of treatment (SVR12), as well as the safety of this regimen in adults or adolescents with chronic HCV GT1-6 infection who have previously failed HCV treatment in AbbVie HCV clinical studies (referred to as the AbbVie HCV Parent Study). The secondary objectives are to evaluate the percentage of subjects who experience virologic failure during HCV treatment and the percentage of subjects who experience HCV virologic relapse.

Primary objective: To determine the pharmacokinetic profile of fenofibric acid after single and multiple doses of ABT-335 in healthy Chinese male and female subjects. Safety objective: To evaluate the safety and tolerability of ABT-335 45 mg and 135 mg capsule formulations after single and multiple doses in healthy Chinese male and female subjects.

To evaluate the pharmacokinetics, safety and tolerability of ABT-493/ABT-530 after repeated oral administration under non-fasting conditions in healthy Chinese adult subjects